Jonggi Choi, Seungbong Han, Namkug Kim, Young‐Suk Lim – 19 June 2017 – Most mortalities from liver disease and liver cancer worldwide are attributable to hepatitis B virus (HBV) and hepatitis C virus. Despite remarkable advances in the treatment of HBV over past decades, limited population‐level data are available regarding its impact on burden of liver disease and liver cancer. Mortality data from liver disease and liver cancer were obtained from the national death certificate database of Korea, an HBV‐endemic country, between 1999 and 2013, and were analyzed by Joinpoint analysis.

George V. Papatheodoridis, Ramazan Idilman, George N. Dalekos, Maria Buti, Heng Chi, Florian van Boemmel, Jose Luis Calleja, Vana Sypsa, John Goulis, Spilios Manolakopoulos, Alessandro Loglio, Spyros Siakavellas, Onur Keskın, Nikolaos Gatselis, Bettina E. Hansen, Maria Lehretz, Juan de la Revilla, Savvoula Savvidou, Anastasia Kourikou, Ioannis Vlachogiannakos, Kostantinos Galanis, Cihan Yurdaydin, Thomas Berg, Massimo Colombo, Rafael Esteban, Harry L.A.

Takeshi Chida, Masahiko Ito, Kenji Nakashima, Yumi Kanegae, Takuya Aoshima, Shuji Takabayashi, Kazuhito Kawata, Yoshimi Nakagawa, Masahiro Yamamoto, Hitoshi Shimano, Tomokazu Matsuura, Yoshimasa Kobayashi, Takafumi Suda, Tetsuro Suzuki – 16 June 2017 – Mechanisms of hepatic fibrogenesis induced by hepatitis C virus (HCV), one of the leading causes of liver fibrosis, are not fully understood.

Minjong Lee, Goh Eun Chung, Jeong‐Hoon Lee, Sohee Oh, Joon Yeul Nam, Young Chang, Hyeki Cho, Hongkeun Ahn, Young Youn Cho, Jeong‐ju Yoo, Yuri Cho, Dong Hyeon Lee, Eun Ju Cho, Su Jong Yu, Dong Ho Lee, Jeong Min Lee, Yoon Jun Kim, Jung‐Hwan Yoon – 15 June 2017 – Antiplatelet therapy has shown protective effects against hepatocellular carcinoma (HCC) in preclinical studies. However, it is unclear whether antiplatelet therapy lowers the risk of HCC in patients with chronic hepatitis B.

Yanik J. Bababekov, Zhi Fong, David C. Chang, Mary Ann Simpson, Heidi Yeh, James J. Pomposelli – 15 June 2017

Sunil Taneja, Yogesh K. Chawla – 15 June 2017

Adam D. Griesemer, Jean C. Emond – 15 June 2017

George Boon‐Bee Goh, James Weiquan Li, Pik‐Eu Chang, Khuan‐Yew Chow, Chee‐Kiat Tan – 14 June 2017 – Hepatocellular carcinoma (HCC) is one of the most common and lethal cancers globally. With advances in therapy for chronic viral hepatitis, changing social circumstances, and increasing practice of HCC surveillance, the epidemiology of HCC is expected to change over time. We explored the temporal trends in HCC in Singapore, a multiethnic Asian country, over the last 3 decades. Patients with HCC were prospectively enrolled and stratified into two cohorts (C1, 1988‐2002; C2, 2003‐2016).

Oluwaseun Falade‐Nwulia, Catherine Sutcliffe, Juhi Moon, Geetanjali Chander, Tanyaporn Wansom, Jeanne Keruly, Jennifer Katzianer, Amy Nathanson, Jillian Marks, Shruti Mehta, David Thomas, Richard Moore, Mark Sulkowski – 13 June 2017 – Hepatitis C virus (HCV) cure rates have been similar in patients with and without human immunodeficiency virus (HIV) coinfection; however, in the ION‐4 study, black patients treated with ledipasvir/sofosbuvir (LDV/SOF) were significantly less likely to achieve cure (90%) compared to nonblack patients (99%).

Yuen Gao, Jinyan Feng, Guang Yang, Shuqin Zhang, Yunxia Liu, Yanan Bu, Mingming Sun, Man Zhao, Fuquan Chen, Weiying Zhang, Lihong Ye, Xiaodong Zhang – 13 June 2017 – Chronic hepatitis B virus (HBV) infection is a leading cause in the occurrence of hepatitis B, liver cirrhosis, and liver cancer, in which nuclear HBV covalently closed circular DNA (cccDNA), the genomic form that templates viral transcription and sustains viral persistence, plays crucial roles.